AAV-hAQP1
AAV2-hAQP1- Radiation-Induced Xerostomia
Market cap $827M 97.7M shares (10-Q, Nov 4, 2026) × $8.46 close Nov 17, 2026
Most recent annual filing: 2026-03-30
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Proprietary synthetic riboswitch technology enabling precise, dose-responsive control of gene expression via oral small molecules; focused on in vivo delivery of metabolic peptides (GLP-1, GIP, glucagon, amylin, PYY, leptin), cell therapy for oncology and autoimmune diseases, and long-term intractable pain
T-cell progenitor-based allogeneic cell therapy platform acquired from Smart Immune; harnesses the patient's own thymus to re-arm the immune system; intended for off-the-shelf allogeneic CAR-T therapies incorporating MeiraGTx riboswitch technology; focus areas include cancer and autoimmune conditions
Proprietary gene regulation platform enabling precise, dose-responsive in vivo delivery of any biologic therapeutic (peptides, hormones, proteins) via oral small molecule inducers. Disease focus areas include metabolic disease (leptin, GLP-1, GIP, Glucagon, Amylin, PYY), cell therapy (CAR-T for liquid/solid tumors and autoimmune diseases), neuropathic/intractable pain, and ophthalmology (gene editing in the eye via Lilly collaboration).
Targets: GLP-1, GIP, Glucagon, Amylin, PYY, Leptin
Proprietary synthetic riboswitch technology enabling precise, dose-responsive expression of any transgene controlled by oral small molecules; focused on in vivo delivery of biologic therapeutics (GLP-1, GIP, glucagon, amylin, PYY, leptin), cell therapy for oncology and autoimmune diseases, and long-term intractable pain.
Broadly applicable gene regulation platform enabling precise, dose-responsive oral small molecule control of transgene expression; gene agnostic and compatible with AAV, lentivirus, CRISPR, or LNP vectors; focus areas include metabolic disease (Ribo-Leptin, GLP-1, GIP, Glucagon, Amylin, PYY, Leptin), neuropathic pain, CAR-T for liquid/solid tumors and autoimmune diseases, and ophthalmology gene editing
Targets: GLP-1, GIP, Glucagon, Amylin, PYY, Leptin
Proprietary intravitreal AAV capsid platform for ocular gene therapy delivery; licensed to Eli Lilly as part of ophthalmology collaboration.
Artificial intelligence-driven platform for generating bespoke gene promoters for ocular and other gene therapy applications; licensed to Eli Lilly as part of ophthalmology collaboration.
Proprietary synthetic riboswitch technology enabling precise, dose-responsive expression of any transgene under control of oral small molecules. Applications include in vivo delivery of metabolic peptides (GLP-1, GIP, glucagon, amylin, PYY, leptin), CAR-T cell therapy for oncology and autoimmune diseases, and gene editing nuclease regulation.
Targets: GLP-1, GIP, glucagon, amylin, PYY, leptin, IL-4, IL-13
Proprietary riboswitch technology enabling in vivo delivery of biologic therapeutics using oral small molecules; allows precise, dose-responsive gene expression regulation. Focus areas include metabolic peptides (GLP-1, GIP, glucagon, amylin, PYY, leptin), CAR-T cell therapy for liquid and solid tumors and autoimmune diseases, and PNS targets for intractable pain.
Broadly applicable platform enabling precise, dose-responsive in vivo control of gene expression via oral small molecules; can be incorporated into any vector (AAV, lentivirus, CRISPR, LNPs); disease focus includes metabolic diseases (GLP-1, GIP, Glucagon, Amylin, PYY, Leptin), neuropathic pain (PNS targets), CAR-T for liquid/solid tumors, and autoimmune diseases
Gene regulation technology platform enabling precise, dose-responsive in vivo control of any biologic therapeutic transgene expression via daily oral small molecule; applications include metabolic peptides (GLP-1, GIP, Glucagon, Amylin, PYY, Leptin), CAR-T (liquid/solid tumors, autoimmune), and PNS targets for neuropathic pain. Delivered via AAV, lentivirus, CRISPR, or LNPs.
Targets: GLP-1, GIP, Glucagon, Amylin, PYY, Leptin
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Every verdict Biotech Distilled has published on MeiraGTx, oldest first — the full history, never a selection. How calls are scored: the track record.
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.
“The MAA dossier is complete and in publishing and the Company intends to submit it to the EMA in December 2026, subject to EMA confirmation of the submission date.”matched to Bota-vec · regulatory submission
Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Sep 23, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →